Stay updated with breaking news from Stevena Shallcross. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ROCKVILLE, Md., May 23, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in
VCN-01 plus gemcitabine and nab-paclitaxel has received fast track designation from the FDA in metastatic pancreatic adenocarcinoma.
VCN-01 is an oncolytic adenovirus intended to selectively replicate within tumor cells and degrade the tumor stroma, breaking down the physical and immunosuppressive barrier to cancer treatment.
VCN-01 was safe and elicited signs of antitumor activity in patients with intraocular retinoblastoma that was refractory to chemotherapy or radiotherapy.
– Lead product candidate, VCN-01 in combination with liposomal irinotecan demonstrated enhanced anti-tumor effects in a human pancreatic mouse xenograft– – The observed synergy emphasizes...